DRESS Syndrome

Comprehensive Clinical Guide: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome

1. Introduction and Clinical Overview

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, also historically referred to as Drug-Induced Hypersensitivity Syndrome (DiHS), is a severe, life-threatening, multi-system adverse drug reaction. Unlike simple cutaneous drug eruptions, DRESS represents a complex T-cell-mediated hypersensitivity reaction that typically manifests between two to eight weeks after the initiation of a culprit medication.

The hallmark of DRESS is its prolonged latency period, which often leads to diagnostic delays as clinicians may not associate the symptoms with a drug initiated weeks prior. The syndrome is characterized by a triad of clinical features: extensive skin rash, hematologic abnormalities (specifically eosinophilia and atypical lymphocytosis), and visceral organ involvement (most commonly the liver, kidneys, lungs, or heart). With a mortality rate ranging from 5% to 10%, early recognition and immediate cessation of the offending agent are critical for patient survival.

2. Etiology and Pathophysiology

The precise pathophysiology of DRESS is multifactorial, involving a complex interplay between drug metabolism, immune system activation, and viral reactivation.

The Immune Mechanism

DRESS is categorized as a Type IVb hypersensitivity reaction. It is driven by the expansion of drug-specific T-cells. When a patient is exposed to a culprit drug, these T-cells infiltrate various tissues, causing systemic inflammation. Key cytokines involved include IL-5 (promoting eosinophilia) and IFN-gamma.

Viral Reactivation Hypothesis

A unique feature of DRESS is its documented association with the reactivation of Human Herpesviruses (HHV). This follows a sequential pattern:
1. Drug Exposure: Initiates the primary immune response.
2. Viral Reactivation: Often begins with HHV-6, followed by EBV (Epstein-Barr Virus), CMV (Cytomegalovirus), or HHV-7.
3. Clinical Escalation: The viral load correlates with the severity of organ damage and the duration of the clinical syndrome.

Genetic Predisposition

Pharmacogenomics plays a significant role in DRESS. Specific HLA alleles have been identified as high-risk markers for certain drug-induced DRESS cases:
* HLA-B*58:01: Highly associated with Allopurinol-induced DRESS.
* HLA-A*31:01: Associated with Carbamazepine-induced DRESS.
* HLA-B*15:02: Associated with Carbamazepine in Asian populations.

3. Clinical Indications and Diagnostic Criteria

Because there is no single "gold standard" test for DRESS, diagnosis is clinical, often utilizing the RegiSCAR scoring system.

The RegiSCAR Scoring System

To diagnose DRESS, a patient must meet at least three of the following criteria:
* Hospitalization: Required for the severity of the reaction.
* Reaction suspected to be drug-related.
* Acute Rash: Present in >50% of the body surface area.
* Fever: Temperature >38°C.
* Enlarged Lymph Nodes: In at least two sites.
* Involvement of at least one internal organ.
* Blood counts: Eosinophilia, atypical lymphocytes, or thrombocytopenia.

Interpretation: >5 points = Definite DRESS; 4 points = Probable; 2-3 points = Possible.

4. High-Risk Medications

The list of medications capable of triggering DRESS is extensive, but the most frequent culprits include:

• Anticonvulsants: Carbamazepine, Phenytoin, Phenobarbital, Lamotrigine.
• Antibiotics: Vancomycin, Sulfonamides, Minocycline, Dapsone.
• Antigout Agents: Allopurinol (notably associated with high mortality in renal impairment).
• Antivirals: Abacavir, Nevirapine.
• Others: Mexiletine, Sulfasalazine.

5. Clinical Staging and Differential Diagnosis

DRESS often mimics other clinical conditions, making differential diagnosis essential.

Differential Diagnosis Table

Clinical Progression

1. Prodromal Phase: Flu-like symptoms, fever, and pharyngitis.
2. Acute Phase: Appearance of the morbilliform rash, facial edema (a classic sign), and lymphadenopathy.
3. Visceral Phase: Onset of hepatitis, interstitial nephritis, or pneumonitis.
4. Recovery Phase: May take weeks to months; potential for autoimmune sequelae.

6. Risks, Side Effects, and Long-Term Prognosis

Immediate Risks

• Fulminant Hepatitis: The leading cause of death in DRESS.
• Hemophagocytic Lymphohistiocytosis (HLH): A severe cytokine storm complication.
• Myocarditis: Often undiagnosed; causes sudden cardiac arrest.

Long-Term Prognosis

While most patients recover with supportive care and corticosteroids, there is a risk of developing autoimmune diseases (e.g., Type 1 Diabetes, Graves’ disease, or Lupus) in the months following the acute phase. Patients must be monitored for at least 6–12 months post-recovery.

7. Management Strategy

• Immediate Action: Discontinue the suspected culprit drug immediately. Cross-reactivity must be considered (e.g., if a patient reacts to one aromatic anticonvulsant, they may react to others).
• Supportive Care: Fluid replacement, nutritional support, and skin care (topical steroids for pruritus).
• Systemic Therapy: Systemic corticosteroids (e.g., Prednisone 0.5–1.0 mg/kg/day) are the standard of care, with a very slow taper over 6–8 weeks to prevent relapse.
• Second-Line: In severe cases, IVIG (Intravenous Immunoglobulin) or Cyclosporine may be utilized.

8. Massive FAQ Section

1. What is the classic timeline for DRESS syndrome?
DRESS typically occurs 2 to 8 weeks after starting a new medication. This long latency distinguishes it from allergic reactions that happen within minutes or hours.

2. Is facial edema a common symptom?
Yes, facial edema is a hallmark sign of DRESS and is present in approximately 75% of cases.

3. Can DRESS be fatal?
Yes. DRESS has a mortality rate of approximately 5–10%, primarily due to liver failure, myocarditis, or secondary infections.

4. Why is tapering steroids important?
DRESS is notorious for "flares." If steroids are discontinued too abruptly, the patient may experience a rebound reaction that is often more severe than the initial presentation.

5. Are all skin rashes DRESS?
No. Most drug rashes are simple maculopapular eruptions. DRESS is specific because it involves systemic organ failure and hematologic markers like eosinophilia.

6. Should I perform a skin biopsy?
A biopsy is useful to rule out SJS/TEN or cutaneous lymphoma, but it is not diagnostic for DRESS. It typically shows perivascular lymphocytic infiltration.

7. Can DRESS affect the kidneys?
Yes, acute interstitial nephritis is a common visceral manifestation of DRESS.

8. What is the significance of the "Atypical Lymphocyte" count?
Atypical lymphocytes resemble those seen in viral infections like mononucleosis; their presence is a strong diagnostic indicator of the immune activation seen in DRESS.

9. Is DRESS contagious?
No, DRESS is not contagious. It is an internal immune response to a drug and the subsequent reactivation of latent viruses within the patient’s own body.

10. Do I need to avoid all drugs if I have had DRESS?
No, but you must avoid the culprit drug and potentially drugs in the same chemical class. A medical alert bracelet and a formal drug allergy list are mandatory for patients with a history of DRESS.

9. Conclusion

DRESS syndrome is a diagnostic challenge that demands high clinical suspicion. Because the symptoms are systemic and the onset is delayed, it is frequently misdiagnosed as an infectious or autoimmune process. Clinicians must maintain a low threshold for investigating drug history in any patient presenting with fever, rash, and eosinophilia. Early intervention—specifically the immediate withdrawal of the offending agent—is the cornerstone of treatment and the primary determinant of a favorable clinical outcome.

As medical science advances, the use of pharmacogenomic testing (e.g., testing for HLA-B*58:01 before prescribing allopurinol) is becoming the standard of care to prevent this devastating condition from occurring in the first place. Continued vigilance and patient education remain the most effective tools in the management of this complex hypersensitivity syndrome.